Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gender-sensitive and diversity-sensitive end-of-life care in Switzerland (GiveCare): a mixed-methods study protocol.

BMJ open·2026

Same author

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Digital and Navigational Health Literacy in Swiss Cancer Survivors Compared With the General Population: Cross-Sectional Questionnaire Study.

Journal of medical Internet research·2026

Same author

24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.

Breast (Edinburgh, Scotland)·2026

Same author

Financial Burden in Adults With Chronic Illness in Switzerland: A Secondary Analysis of Qualitative Interviews Using Natural Language Processing and Topic Modeling.

JMIR formative research·2026

Same author

Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention.

JAMA·2025

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Do aromatase inhibitors have adverse effects on cognitive function?

Kelly Anne Phillips¹, Karin Ribi, Richard Fisher

¹Division of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, 3002, Australia. Kelly.Phillips@petermac.org

Breast Cancer Research : BCR

|March 12, 2011

Summary

This summary is machine-generated.

Aromatase inhibitors, used for breast cancer, do not appear to cause cognitive dysfunction in postmenopausal women. Current evidence suggests they are not worse than tamoxifen for cognitive effects, but more research is needed.

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 3, 2026

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Area of Science:

Oncology
Neuroscience
Endocrinology

Background:

Aromatase inhibitors (AIs) are standard treatment for hormone receptor-positive, early-stage breast cancer in postmenopausal women.
AIs significantly reduce circulating estrogen levels.
Estrogen plays a crucial role in cognitive function, raising concerns about potential AI-induced cognitive side effects.

Purpose of the Study:

To evaluate the impact of aromatase inhibitors on cognitive function in postmenopausal women with early-stage breast cancer.
To compare the cognitive effects of aromatase inhibitors with tamoxifen.

Main Methods:

Systematic review and analysis of existing studies, including data from large randomized trials.
Studies were assessed for their power to detect moderate to small effects on cognition.

Main Results:

Available data do not support the hypothesis that aromatase inhibitors adversely affect cognitive function.
There is no clear evidence that aromatase inhibitors have a more adverse effect on cognition compared to tamoxifen.
The reviewed studies were adequately powered to detect moderate cognitive effects, but not small effects.

Conclusions:

Current evidence does not indicate that aromatase inhibitors negatively impact cognitive function in this patient population.
Further research is required to definitively confirm these findings and investigate potential small effects.